Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Gyre Therapeutics (GYRE) Shares Outstanding (2016 - 2025)

Gyre Therapeutics (GYRE) has disclosed Shares Outstanding for 16 consecutive years, with $91.3 million as the latest value for Q4 2025.

  • Quarterly Shares Outstanding rose 5.8% to $91.3 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $91.3 million through Dec 2025, up 5.8% year-over-year, with the annual reading at $91.3 million for FY2025, 5.8% up from the prior year.
  • Shares Outstanding for Q4 2025 was $91.3 million at Gyre Therapeutics, roughly flat from $90.9 million in the prior quarter.
  • The five-year high for Shares Outstanding was $91.3 million in Q4 2025, with the low at $31.3 million in Q1 2021.
  • Average Shares Outstanding over 5 years is $64.3 million, with a median of $63.6 million recorded in 2021.
  • The sharpest move saw Shares Outstanding skyrocketed 187.76% in 2021, then changed 0.0% in 2022.
  • Over 5 years, Shares Outstanding stood at $63.6 million in 2021, then changed by 0.0% to $63.6 million in 2022, then increased by 20.46% to $76.6 million in 2023, then grew by 12.68% to $86.3 million in 2024, then grew by 5.8% to $91.3 million in 2025.
  • According to Business Quant data, Shares Outstanding over the past three periods came in at $91.3 million, $90.9 million, and $90.8 million for Q4 2025, Q3 2025, and Q2 2025 respectively.